All Articles

Ibrutinib is the only once-daily Bruton tyrosine kinase inhibitor that has shown significant progression-free survival (PFS) and overall survival (OS) benefits in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) across multiple randomized phase 3 studies.

Oncology nurse navigators and multidisciplinary models of care have been shown to improve outcomes for patients with cancer.

The UT Southwestern Cancer Genetics Program implemented a genetic patient navigator (GPN) to assess patients’ barriers to care, assist patients in identifying resources to increase compliance, promote healthy lifestyle education, and assist with coordination of cascade testing for at-risk relatives.

Lung cancer has the highest mortality rate of all tumor sites.

Nassau and Suffolk counties on Long Island account for over 1500 breast cancer diagnoses annually.

The use of acuity scales to assess cancer patient needs when undergoing treatment is gaining recognition as a way to optimize caseloads for patient navigators (PNs).

A 21-year-old with carcinoma of the nasopharynx was first evaluated by the Head and Neck Oncology Service at Memorial Sloan Kettering Cancer Center (MSKCC) in April 2020.

The process of screening and/or detection to the actual diagnosis of lung cancer involves multiple specialties and diagnostic testing, which can be quite daunting for an individual and his/her family.

Low enrollment rates for cancer clinical trials have been an ongoing barrier to scientific advances in oncology care.

Kenyatta National Hospital (KNH) is the main public hospital in Kenya delivering comprehensive cancer care and receives patients from throughout the country.